New hope for hospital patients: drug may shield kidneys from toxic meds
NCT ID NCT06886464
First seen Jan 07, 2026 · Last updated May 20, 2026 · Updated 23 times
Summary
This study tests whether cilastatin, a drug already used for other purposes, can prevent acute kidney injury in hospitalized patients who must take medications known to harm the kidneys. About 700 adults receiving certain antibiotics, chemotherapy, or contrast dyes will receive either cilastatin or a placebo every 6 hours. Researchers will monitor kidney function daily and follow up at 90 days to see if the drug reduces injury.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Alberta
RECRUITINGEdmonton, Alberta, T6G 2R3, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Calgary
RECRUITINGCalgary, Alberta, T2N 1N4, Canada
Conditions
Explore the condition pages connected to this study.